Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy.
Giuseppe
G
Visani
Hematology, Ca'Foncello Hospital, Treviso, Italy.
Pietro Maria
PM
Stefani
Department of Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Saveria
S
Capria
Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy.
Lara
L
Malerba
Hematology, Ascoli Piceno, Italy.
Piero
P
Galieni
Division of Hematology, University of Bari Medical School, Bari, Italy.
Francesco
F
Gaudio
Division of Hematology, University of Bari Medical School, Bari, Italy.
Giorgina
G
Specchia
Department of Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Giovanna
G
Meloni
Hematology, Ca'Foncello Hospital, Treviso, Italy.
Filippo
F
Gherlinzoni
Hematology, San Martino Hospital, Genova, Italy.
Roberta
R
Gonella
Hematology, San Martino Hospital, Genova, Italy.
Marco
M
Gobbi
Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy.
Armando
A
Santoro
Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy.
Felicetto
F
Ferrara
Institute of Biomathematics, Urbino University, Urbino, Italy.
Marco
M
Rocchi
Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca, Salamanca, Spain.
Enrique M
EM
Ocio
Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca, Salamanca, Spain.
Maria Dolores
MD
Caballero
Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy.
Federica
F
Loscocco
Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy.
Alessandro
A
Isidori
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008558:Melphalan / Q000627:therapeutic use; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D014182:Transplantation, Autologous
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D003561:Cytarabine; D000069461:Bendamustine Hydrochloride; D008558:Melphalan